A phase 1/2 trial of MT218 injection in prostate cancer, run by Songqi Gao, now recruiting.
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients is a phase 1/2 interventional study registered as NCT06262139 by Songqi Gao, with 12 participants planned, started 2024-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: MT218 injection.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.